Tolerability of Icelandic Moss Lozenges in Upper Respiratory Tract Diseases – Multicentric Drug Monitoring Study with 3,143 Children Background and Objective: Icelandic moss is a medical herb with therapeutic efficacy in inflammatory airway diseases. Although preparations based on the extract of this lichen have been marketed since the 19th century, their tolerability has not yet been investigated systematically. Patients and Methods: The tolerability of Isla-Moos® and Isla-Mint® lozenges and the changes of clinical symptoms during treatment were investigated in a post-marketing surveillance study performed in 300 predominantly pediatric practices in Germany. The preparations contained 80 and 100 mg, respectively, of an aqueous Icelandic moss extract. 3,143 children between 4 and 12 years of age who suffered from upper respiratory tract diseases received Isla-Moos® (n = 1,848) or Isla-Mint® (n = 1,295) over a period of 1–2 weeks; 61% of the children received 4–6 lozenges per day. Tolerability was evaluated by assessing adverse drug reactions (ADRs). Treatment success was assessed globally by the investigators and the patients’ parents. The parents were also asked to rate their children’s symptoms before and after treatment. Results: During the period of observation, 73 adverse events, most of which were related to the basic disease, were reported in 57 children (1.8%). In 6 children (0.2%) and 7 events (2× itching, 2× nausea, 1× abdominal pain, 1× heartburn, 1× burning in the mouth) a causal relationship with Icelandic moss extract could not be excluded, so that they were evaluated as ADRs. All ADRs subsided spontaneously during the period of observation. The incidence of ADRs was 1 event in 3,008 (95% confidence interval: 1,504–7,019) treatment days. As regards clinical symptoms, 39% of the children were fully recovered and another 55% were improved by the end of the period of observation. Conclusions: During treatment of 4- to 12-year-old children with Isla-Moos® and Isla-Mint® lozenges only isolated, trivial, and transient adverse drug reactions were observed. The results thus confirm the good tolerability of both drugs and support a favorable risk-benefit assessment.

This content is only available via PDF.
© 2004 S. Karger GmbH, Freiburg
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.